Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in Korean Patients With Moderately to Severely Active Ulcerative Colitis
NCT06964113Phase 4Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of filgotinib in ulcerative colitis (UC), sponsored by Eisai Co., Ltd. Primary endpoint: Percentage of Participants Achieving Clinical Remission at 22 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
filgotinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06964113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964113.